ETON

Eton Pharmaceuticals, Inc. (ETON) Scenario Analysis Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Base Case

ETON shows solid profitability and cash generation, with net profit margin at 12.0%, ROIC at 20.4%, and current ratio at 1.52.

Valuation remains demanding at 15.97x EV/Sales and 114.46x EV/FCF, which limits upside in a steady-state scenario.

Balance sheet leverage is modest with net debt to EBITDA at 0.12x, supporting downside resilience.

Bull Case

High gross margin of 57.9% and ROE of 40.1% indicate strong operating leverage if growth accelerates.

Low net debt and strong interest coverage of 6.14x provide room for execution upside.

If revenue growth improves, the current premium multiple could be partially justified by the company’s profitability profile.

Bear Case

The stock is priced for perfection, with P/E at 132.2x and price to free cash flow at 114.3x, leaving little margin for error.

Free cash flow yield is only 0.87%, so any slowdown in cash conversion could pressure the valuation.

Working capital intensity remains meaningful, with a 51.1-day cash conversion cycle and 86.0 days sales outstanding.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Eton Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →